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Abstract
Aims A prospective meta-analysis of phase 3 trials showed lower rates of nocturnal hypoglycaemia with insulin
degludec vs. insulin glargine. We investigated the consistency of the results across different definitions of hypoglycaemia.
Methods This post-hoc, patient-level meta-analysis included six randomized, controlled, 26- or 52-week phase 3a
trials in insulin-na€ıve participants with Type 2 diabetes mellitus (Type 2 diabetesinsulin na€ıve), participants with Type 2
diabetes mellitus using basalbolus therapy (Type 2 diabetesBB) and those with Type 1 diabetes mellitus. We used three
definitions of hypoglycaemia and different timescales for the nocturnal period. Rates were analysed for the entire core
trial period, the ‘maintenance period’ only, and the extension trial set population. Analyses utilized a negative binomial
regression model.
Results In Type 2 diabetesinsulin na€ıve participants, risk of nocturnal hypoglycaemia was significantly lower with insulin
degludec vs. insulin glargine for all hypoglycaemia definitions and trial periods. Risk was also lower for the timescale
21.59–05.59, but not 00.01–07.59. For Type 2 diabetesBB, nocturnal hypoglycaemia rates were lower with insulin
degludec vs. insulin glargine across all definitions, timescales and trial periods, with one exception. For individuals with
Type 1 diabetes mellitus, nocturnal hypoglycaemia risk was significantly lower with insulin degludec during the
maintenance period for the original definition (plasma glucose < 3.1 mmol/l, timescale 00.01–05.59) and in the
extension trial set population for all hypoglycaemia definitions except for the nocturnal timescale 00.01–07.59.
Conclusions Compared with insulin glargine, insulin degludec is associated with lower rates of nocturnal hypogly-
caemia in people with Type 2 diabetes mellitus, and similar or lower rates in Type 1 diabetes mellitus, across different
definitions.
Diabet. Med. 33, 478–487 (2016)
Introduction
Insulin degludec is a recently developed basal insulin
analogue with an ultra-long duration of action and a flatter
and more stable pharmacokinetic and pharmacodynamic
profile, with less variability in glucose-lowering activity,
compared with insulin glargine [1,2]. The efficacy and safety
of insulin degludec have been examined in an extensive
phase 3a programme (BEGIN). This included seven treat-to-
target clinical trials in which insulin degludec was compared
with insulin glargine [3–9], showing similar glycaemic
control when titrated to the same targets. A prospectively
planned meta-analysis of the seven trials showed that rates of
overall and nocturnal hypoglycaemia were significantly
lower with insulin degludec compared with insulin glargine
in participants with Type 2 diabetes mellitus [10]. This meta-
analysis was made possible because a consistent definition of
hypoglycaemia was used in all the trials: self-reported
confirmed events with plasma glucose < 3.1 mmol/l
(56 mg/dl), or severe events requiring assistance. Nocturnal
events were defined as those occurring between 00.01 and
05.59, inclusive [10].
Lower rates of nocturnal hypoglycaemia may have specific
benefits, as even non-severe nocturnal hypoglycaemic events
have been shown to have a greater negative impact on
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patients than previously believed, affecting their sleep and
their functioning and productivity the next day [11,12]. The
development of nocturnal hypoglycaemia is particularly
problematic because basal insulins have traditionally been
titrated to ambitious fasting plasma glucose targets with
evening dosing.
The threshold value of 3.1 mmol/l for defining hypogly-
caemia was chosen because it represented a degree of
hypoglycaemia at which patients typically report symptoms
[10,13] and was in line with the guidelines of the European
Medicines Agency at the time [14]. For physicians who are
deciding on the best choice of therapy for patients with
problematic hypoglycaemia, it is important to know whether
the benefit seen with insulin degludec is consistent across
different definitions. Therefore, in the analyses reported here,
we investigated how robust the estimated rate differences are
when the sensitivity or specificity of the hypoglycaemia
definition is changed. The sensitivity of the definition was
increased by considering the American Diabetes Association
(ADA) cut-off for defining hypoglycaemia [blood glucose
< 3.9 mmol/l (70 mg/dl)] [15], whereas the specificity was
increased by restricting the definition to cover only hypogly-
caemic events that were reported with symptoms. Further-
more, we also expanded the time interval for nocturnal
hypoglycaemia by 2 h either in the late evening or in the
early morning. Additionally, we investigated whether the
titration of the insulin preparation influenced the treatment
difference, by considering rate ratios in the maintenance
period, and finally whether the treatment difference was
sustained in the long term, by including finalized extension
trials in the analysis.
Methods
This post-hoc, patient-level meta-analysis included six ran-
domized, controlled, open-label, multicentre, phase 3a,
treat-to-target trials of 26 or 52 weeks’ duration in partic-
ipants with diabetes. Trials were categorized as in the
original prospectively planned meta-analysis; for Type 2
diabetes mellitus, analysis was restricted to trials in which
participants were either insulin-na€ıve or using a basal–bolus
regimen [10]. Three trials were in insulin-na€ıve participants
with Type 2 diabetes mellitus (Type 2 diabetesinsulin na€ıve);
one trial was in participants with Type 2 diabetes mellitus
treated with a basal–bolus regimen (Type 2 diabetesBB); and
two trials were in participants with Type 1 diabetes mellitus.
The BEGIN FLEX trial, which enrolled both insulin-na€ıve
participants and those already on basal insulin [6], was
therefore excluded. All trials were registered at Clinicaltri-
als.gov as follows: BEGIN Once Long and BEGIN Once
Long extension: NCT00982644; BEGIN Once Asia:
NCT01059799; BEGIN Low Volume: NCT01068665;
BEGIN BB: NCT00972283; BEGIN BB extension:
NCT01190956; BEGIN BB T1 Long: NCT00982228;
BEGIN BB T1 Long extension: NCT01193322; BEGIN Flex
T1 and BEGIN FLEX T1 Extension: NCT01079234.
In all the trials, confirmed hypoglycaemia was defined as
episodes with a measured plasma glucose concentration of
< 3.1 mmol/l or severe episodes necessitating assistance, and
the nocturnal period was defined as 00.01–05.59 inclusive. In
addition to this original definition, we performed sensitivity
analyses using two further definitions for reporting hypogly-
caemia: only confirmed hypoglycaemic episodes that were
accompanied by symptoms (i.e. a more specific definition)
and the ADA definition (symptomatic event and plasma
glucose ≤3.9 mmol/l, i.e. a more sensitive definition). To test
the robustness of the results, we also performed analyses in
which 2 h were added to either end of the nocturnal period
(Fig. 1).
Furthermore, we analysed rates of nocturnal hypogly-
caemia for different trial periods: the entire core trial
period, the ‘maintenance period’ only and the extension
period (Table 1). In the BEGIN trial programme, separate
analysis of the maintenance period (week 16 onwards,
after stable glycaemic control and stable insulin dose had
usually been achieved following active titration) was
included at the specific request of the regulatory author-
ities. The extension period applied to the four trials that
were continued for a longer duration (one trial in Type 2
diabetesinsulin na€ıve, one trial in Type 2 diabetesBB and two
trials in Type 1 diabetes mellitus) (Table 1) [9,16–18]. In
the analyses reported here, the term ‘extension set’ refers
to the full duration of the trials concerned (core trial plus
extension period).
The number of episodes was analysed using the same
model that was employed in the previous meta-analysis – a
negative binomial regression model using a log link and the
logarithm of the exposure time (100 years) as offset. The
model included treatment, sex, region, anti-diabetic treat-
ment at screening and trial as fixed effects and age as
covariate. For the Type 2 diabetesBB group, trial was not
What’s new?
• This meta-analysis investigated the rate of nocturnal
hypoglycaemia using different definitions of hypogly-
caemia and of the nocturnal timescale in participants
treated with insulin glargine or insulin degludec from
phase 3a trials.
• Insulin degludec was associated with lower rates of
nocturnal hypoglycaemia in participants with Type 2
diabetes mellitus, and lower or similar rates in
participants with Type 1 diabetes mellitus across all
definitions.
• Insulin degludec may help patients reach and maintain
glucose targets, and reduce the frequency of nocturnal
hypoglycaemia and its negative impact on patients’
daily lives.
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included as a covariate. The results are shown as estimated
treatment rate ratios with their two-sided 95% confidence
intervals (CIs).
Results
Trial characteristics and study participants
Demographic characteristics for the groups in each trial are
shown in Table 2. In each trial, baseline characteristics and
demographics and withdrawal rates were similar between
treatment groups.
For all the patient populations, the estimated number of
episodes per 100 patient-years of exposure (PYE) are shown
in Table 3.
Insulin-na€ıve people with Type 2 diabetes mellitus
From Table 3(a) it can be seen that for the Type 2
diabetesinsulin na€ıve population, estimated rates of nocturnal
hypoglycaemia were consistently lower with insulin degludec
vs. insulin glargine, with the difference ranging between 5
and 44 episodes per 100 PYE, depending on definition of
hypoglycaemia and nocturnal period. For this population,
treatment with insulin degludec was associated with signif-
icantly lower rates of nocturnal hypoglycaemia using all
three definitions for reporting hypoglycaemia, and for all
trial periods (Fig. 2a).
With different defined times for the nocturnal period, these
participants still had a lower risk of nocturnal hypogly-
caemia with insulin degludec compared with insulin glargine
for the period between 21.59 and 05.59 (Fig. 2a). For the
extended timescale of 0.01–07.59, however, the risk was
lower only during the maintenance period. It is notable that
adding these two morning hours to the definition resulted in
a two- to threefold increase in the number of episodes per
100 PYE (e.g. from 24.3 to 75.1 with insulin degludec, and
from 38.0 to 80.7 with insulin glargine, for the entire period)
(Table 3a).
Participants with Type 2 diabetes mellitus using basalbolus
therapy
For the Type 2 diabetesBB participants, estimated rates of
nocturnal hypoglycaemia were lower with insulin degludec
vs. insulin glargine by between 37 and 74 episodes per
100 PYE across the different definitions (Table 3b). Treat-
ment with insulin degludec was associated with significantly
lower rates of nocturnal hypoglycaemia across all definitions,
all nocturnal timescales and all trial periods, compared with
insulin glargine, with one exception: in the original defini-
tion, the 95% CI upper limit reached 1 for the maintenance
period (Fig. 2b).
Participants with Type 1 diabetes mellitus
For participants with Type 1 diabetes mellitus, estimated
rates of nocturnal hypoglycaemia were lower with insulin
degludec vs. insulin glargine by between 97 and 203 episodes
per 100 PYE, depending on the definition used, with one
exception: the nocturnal hypoglycaemia rate was 2 episodes
per 100 PYE higher with insulin degludec for the core trial
period when the nocturnal period was defined as 0.01–07.59
(Table 3c). The risk of nocturnal hypoglycaemia did not
FIGURE 1 Description of the different analyses that were conducted.
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differ significantly between the treatment groups for any of
the definitions or nocturnal timescales, during the entire core
trial period (Fig. 2c). During the maintenance period, the risk
was significantly lower with insulin degludec only when
using the original definition for reporting hypoglycaemia. In
the extension set, the risk of nocturnal hypoglycaemia was
significantly lower with insulin degludec for all the defini-
tions and for the nocturnal timescale 21.59–05.59.
Discussion
These post-hoc analyses are relevant to practising clinicians
because they confirm that differences previously reported
between insulin degludec and insulin glargine in rates of
nocturnal hypoglycaemia are not dependent on the definition
used in the BEGIN trial programme. In general, in each
population analysed (Type 2 diabetesinsulin na€ıve, Type 2
diabetesBB, Type 1 diabetes mellitus), the treatment differ-
ences for nocturnal hypoglycaemia were similar for different
definitions of hypoglycaemia and different trial periods. The
results also show that the lower risk of nocturnal hypogly-
caemia seen with insulin degludec vs. insulin glargine in
Type 2 diabetes mellitus is maintained across different
definitions.
One exception to the pattern was seen when the nocturnal
timescale was extended to 0.01–07.59. In the Type 2
diabetesinsulin na€ıve population, the rate ratio was no longer
significantly in favour of insulin degludec. For this definition
Table 1 Summary of phase 3a trials comparing insulin degludec with insulin glargine included in the current analysis
Category Type 2 diabetes mellitus (insulin na€ıve)
Type 2 diabetes
mellitus
(basal–bolus) Type 1 diabetes mellitus
Trial BEGIN Once
Long
BEGIN Once
Asia
BEGIN Low
Volume
BEGIN BB BEGIN BB
T1 Long
BEGIN Flex T1
Core trial [ref] 3579 [8] 3586 [7] 3672 [4] 3582 [3] 3583 [5] 3770* [9]
Treatment IDeg OD or
IGlar OD +
met  DPP–4i
IDeg OD or
IGlar OD +
OAD except
DPP–4i
IDeg 200
U/mL OD
or IGlar OD +
met  DPP–4i
IDeg OD or
IGlar OD +
IAsp TID 
met  PIO
IDeg OD
or IGlar OD +
IAsp TID
IDeg OD
or IGlar OD +
IAsp TID
Duration of core trial
(weeks)
52 26 26 52 52 26
Randomization ratio 3:1 2:1 1:1 3:1 3:1 1:1
N in full analysis set:
IDeg 773 289 228 744 472 165
IGlar 257 146 229 248 157 164
n (%) completing core trial:
IDeg 607 (79) 258 (89) 200 (87) 618 (82) 404 (86) 139 (84)
IGlar 197 (77) 136 (93) 201 (87) 211 (84) 137 (87) 152 (93)
n analysed in the meta-analysis:
IDeg 1290 744 637
IGlar 632 248 321
Extension trial [ref] 3643 [18] – – 3667 [16] 3644 [17] 3770-Ext [9]
Duration of
extension period
(weeks)
52 – – 26 52 26
Total duration
(weeks)
104 – – 78 104 52
n entering extension trial (% of core trial)†:
IDeg 551 (71) – – 566 (76) 351 (74) 239 (73)‡
IGlar 174 (68) 191 (77) 118 (75) 133 (81)
n completing extension trial (% of core trial)†:
IDeg 505 (65) – – 539 (71) 330 (70) 223 (68)†
IGlar 154 (60) 183 (73) 113 (72) 122 (74)
n analysed in the meta-analysis:
IDeg 1290 744 801
IGlar 632 248 321
*Trial 3770 included a third dosing arm with ‘forced-flexible’ dosing intervals of 8 and 40 h (n = 164). This dosing arm was excluded from
this meta-analysis as the extreme forced-flexible dosing regimen does not represent the recommended use of insulin degludec in clinical
practice.
†Numbers shown are those entering/completing the extension trial, as a percentage of the number randomized at baseline in the core trial.
‡Patients from the ‘forced-flexible’ arm entered the ‘free-flexible’ extension phase together with patients who had received IDeg OD in the
core trial. The percentage is thus based on all patients who received IDeg in the core trial (IDeg OD 165, IDeg forced-flexible 164, total
n = 329). The analysis for the extension set covered all the patients over the whole period regardless of their initial treatment.
BB, basal–bolus; DPP–4i, dipeptidyl peptidase–4 inhibitor; IAsp, insulin aspart; IDeg, insulin degludec; IGlar, insulin glargine; met,
metformin; OAD, oral antidiabetic drug; OD, once daily; PIO, pioglitazone; TID, three times daily.
ª 2015 The Authors.
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events increased threefold, suggesting that this expansion
was driven not by nocturnal hypoglycaemia, but by morning
events. This might be the result of a later waking time, or
diabetes therapies taken at breakfast. One possible
contributing factor may have been that pre-breakfast plasma
glucose testing was prescribed by the study protocols for
Table 3 Estimated rates of hypoglycaemia
Episodes per 100 PYE
(least squares means
estimate)
IDeg IGlar
(a) Type 2 diabetes mellitus insulin na€ıve IDeg N = 1279, IGlar N = 631
Nocturnal confirmed hypoglycaemia (original definition)* (00.01–05.59) Entire period 24.3 38.0
Maintenance period 26.8 52.6
Extension set 24.2 41.7
Nocturnal confirmed symptomatic hypoglycaemia† (00.01–05.59) Entire period 15.7 28.1
Maintenance period 17.2 40.4
Extension set 14.8 29.4
Nocturnal ADA documented symptomatic hypoglycaemia‡ (00.01–05.59) Entire period 73.8 100.5
Maintenance period 70.6 114.7
Extension set 73.3 105.9
Nocturnal confirmed hypoglycaemia (21.59–05.59)§ Entire period 25.8 42.8
Maintenance period 29.5 60.1
Extension set 25.1 45.1
Nocturnal confirmed hypoglycaemia (00.01–07.59)§ Entire period 75.1 80.7
Maintenance period 77.3 101.5
Extension set 75.1 82.5
(b) Type 2 diabetes mellitus basal–bolus IDeg N = 742, IGlar N = 248
Nocturnal confirmed hypoglycaemia (original definition)* (00.01–05.59) Entire period 112.7 149.3
Maintenance period 101.0 141.2
Extension set 126.6 177.4
Nocturnal confirmed symptomatic hypoglycaemia† (00.01–05.59) Entire period 90.1 133.0
132.8
125.1
Maintenance period 86.2
Extension set 84.5
Nocturnal ADA documented symptomatic hypoglycaemia‡ (00.01–05.59) Entire period 167.0 233.4
Maintenance period 148.7 211.6
Extension set 158.8 212.6
Nocturnal confirmed hypoglycaemia (21.59–05.59)§ Entire period 195.8 268.3
Maintenance period 174.4 247.6
Extension set 178.7 238.3
Nocturnal confirmed hypoglycaemia (00.01–07.59)§ Entire period 168.7 220.0
Maintenance period 133.8 192.0
Extension set 153.2 199.5
(c) Type 1 diabetes mellitus IDeg N = 637, IGlar N = 316; Extension trials¶ IDeg N = 801, IGlar N = 316
Nocturnal confirmed hypoglycaemia (original definition)* (00.01–05.59) Entire period 596.8 718.5
Maintenance period 499.5 664.5
Extension set 445.4 648.6
Nocturnal confirmed symptomatic hypoglycaemia† (00.01–05.59) Entire period 507.6 577.0
Maintenance period 434.9 535.1
Extension set 418.1 535.5
Nocturnal ADA documented symptomatic hypoglycaemia‡ (00.01–05.59) Entire period 768.5 846.0
Maintenance period 684.0 788.2
Extension set 633.1 777.0
Nocturnal confirmed hypoglycaemia (21.59–05.59)§ Entire period 1103 1250
Maintenance period 934.2 1104.0
Extension set 957.3 1134.6
Nocturnal confirmed hypoglycaemia (00.01–07.59)§ Entire period 1566 1564
Maintenance period 1309.9 1445.4
Extension set 1292.9 1389.5
*PG < 3.1 mmol/l (56 mg/dl) or severe hypoglycaemia requiring assistance.
†Confirmed hypoglycaemia with symptoms.
‡ADA definition [symptoms + PG < 3.9 mmol/l (70 mg/dl)].
§Original definition with time of ‘nocturnal’ varied.
¶The extension of trial 3770 included patients from the forced-flexible dosing arm of the main trial. Forced-flexible dosing was stopped
during the extension and all patients treated with IDeg followed a free-flexible dosing regimen, administering IDeg at any time of day
provided they maintained a minimum of 8 and a maximum of 40 hours between doses.
IDeg, insulin degludec; IGlar, insulin glargine; PYE, patient-year of exposure.
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insulin titration decisions, and that asymptomatic hypogly-
caemia, which would have gone unrecorded, was therefore
detected. It is also possible that, unlike insulin glargine where
plasma insulin levels may have begun to fall, the effect of
insulin degludec, which has a flat pharmacokinetic profile,
may have combined with other breakfast glucose-lowering
medication, and so caused a shift in the relative risk.
Extending the definition of nocturnal timescale also
affected data in the Type 1 diabetes mellitus population.
Rates increased 2.5-fold in this group when the nocturnal
period was defined as 0.01–07.59; this increase may repre-
sent the effects of mealtime bolus insulin therapy in combi-
nation with the sustained concentration of insulin degludec.
The rate ratio remained numerically in favour of insulin
degludec in the majority of analyses performed.
The separate analysis of the maintenance period (week 16
onwards), which was suggested by the regulatory authorities
for the BEGIN trial programme, was intended to exclude
possible differences due to the titration process arising from
physicians’ and patients’ greater familiarity with insulin
glargine. The maintenance period was also where participants
were most likely to be for a significant portion of their therapy
and is hence clinically relevant. In the current analyses, a
greater benefit was seen with insulin degludec in the main-
tenance period compared with the core trial period across all
definitions. This difference could partially be explained by the
fact that for participants treated with pre-trial doses of twice-
daily basal insulin in the BEGIN trials, there was a 1:1 switch
to insulin degludec but a 20–30% reduction for insulin
glargine, in line with its prescribing information. In fact,
absolute event rates were low, and final total insulin doses
were similar for both insulins or greater with insulin glargine.
This suggests that, in accordance with the prescribing
information, physicians may want to consider dose reduction
of insulin degludec when switching people with Type 1
diabetes mellitus who are using twice-daily basal insulin or
whose HbA1c < 64 mmol/mol (8.0%) at the time of transfer.
Compared with the core trial sets, the risk ratios for the
extension sets appeared to be more favourable for insulin
degludec in the Type 2 diabetesinsulin na€ıve and Type 1
diabetes populations. In the extension study in Type 2
diabetesinsulin na€ıve [18] and one of the extension studies in
Type 1 diabetes [17], the hypoglycaemia curves did indeed
show increased between-group differences in the risk of
nocturnal hypoglycaemia over time. This suggests that the
risk reduction with insulin degludec is a sustained effect and
may improve as patients learn to optimize the use of this new
insulin – although these promising results need to be
balanced against the limitations of extension studies in
which those who perceive little benefit from insulin degludec
may be less likely to participate.
Even non-severe nocturnal hypoglycaemia has been shown
to negatively affect patients’ functioning and well-being, and
may potentially lead to suboptimal glycaemic control [12].
The reported reductions in risk of nocturnal hypoglycaemia
across categories, particularly in Type 2 diabetes mellitus,
are thus both statistically significant and clinically relevant.
Given that rates of severe hypoglycaemia were low in all the
trials over the full 24-h period [10], meta-analyses were not
conducted for nocturnal severe hypoglycaemia.
In studies that enrolled participants receiving bolus as well
as basal insulin, the between-treatment differences were less
pronounced than in those in which participants received
basal insulin only. A possible explanation is that, once people
start using a bolus insulin, most hypoglycaemia will arise
from the bolus insulin, confounding differences between
basal insulins. Nevertheless, there may be a need for a
different adaptation of bolus dosing on a background of
insulin degludec, in particular in combination with exercise.
In real life, any clinical benefits observed with a new drug,
such as reduction in hypoglycaemia and increased conve-
nience of administration, have to be balanced against
differences in cost. Pharmacoeconomic modelling studies
based on a UK perspective suggest that insulin degludec is a
cost-effective option compared with insulin glargine in
selected people with Type 1 diabetes [19] and Type 2
diabetes [20]. These studies suggested that insulin degludec
would be particularly cost-effective for subgroups of
patients, such as those with recurrent nocturnal hypogly-
caemia or impaired awareness of hypoglycaemia. This has
further been confirmed by recent ‘real-life’ observational
studies from routine clinical practice from both Sweden [21]
and the UK [22], which concluded that the cost of insulin
degludec compared with glargine could be considered justi-
fied in selected patients (mainly with Type 1 diabetes, but
including some with Type 2 diabetes) based on the clinical
benefits achieved.
A limitation of these analyses is that they were based on
studies in which a different dose adjustment was used for
insulin degludec and insulin glargine when switching partic-
ipants who were using insulin glargine twice daily, and
administration times were different (evening for insulin
degludec vs. any time for insulin glargine, reflecting the
licensing of insulin glargine). When interpreting the results
for the extension period, it must be remembered that some
participants dropped out, although the numbers doing so
during the extension phase were relatively small (Table 1).
There are also some limitations with regard to the
statistical analysis. It was important to use the same model
as that used in the earlier pre-specified meta-analysis [10],
because we wanted to test the effects of different definitions
of nocturnal hypoglycaemia, without any possible confound-
ing arising from different statistical models. For this reason,
we did not model the effects of the regressors flexibly, nor did
we test alternative statistical models and their fit. Further-
more, in the current study, we decided not to perform
sensitivity analyses, as two sensitivity analyses that were
performed for the pre-specified meta-analysis (using the
pooled Type 2 and Type 1 diabetes mellitus populations)
yielded results that were consistent with the main analysis
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FIGURE 2 Rate ratios (insulin degludec insulin glargine) for nocturnal confirmed hypoglycaemia, using different definitions for reporting
hypoglycaemia and different timescales for the nocturnal period. Results are shown for the entire core trial period, the maintenance period only and
the extension set (i.e. core trials plus extension periods). (a) Insulin-na€ıve patients with Type 2 diabetes mellitus, (b) basal–bolus-treated patients with
Type 2 diabetes mellitus, (c) patients with Type 1 diabetes mellitus. Dark blue, entire core trial period; light blue, maintenance period only (from
week 16 onwards); grey, extension set (core trial plus extension period). *P < 0.05. (a) Plasma glucose < 3.1 mmol/l or severe hypoglycaemia
requiring assistance. (b) Confirmed hypoglycaemia with symptoms. (c) ADA definition (symptoms + plasma glucose ≤ 3.9 mmol/l). (d) Original
definition with timescale of ‘nocturnal’ varied.
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[10]. The first sensitivity analysis used a random effects
rather than a fixed effects approach; the second fitted the
model without covariates other than treatment, type of
diabetes and trial. Finally, participants in the BEGIN Flex T1
trial who were in an arm that used a forced-flexible regimen
during the core period were excluded from the core period
analysis; however, in the extension period analysis, these
participants’ hypoglycaemia rates were analysed over the
whole trial period.
In conclusion, these data confirm previous findings, show-
ing that compared with insulin glargine, insulin degludec is
associated with significantly lower rates of nocturnal hypo-
glycaemia in people with Type 2 diabetes mellitus, and
similar or lower rates in Type 1 diabetes mellitus. Insulin
degludec may therefore help patients with nocturnal hypo-
glycaemia to reach and maintain tight glucose targets.
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